TENX

Tenax is a development-stage pharmaceutical company with no product revenue at all — FY2025 revenue was $0.00, as was FY2024, and the history back to FY2021 shows the company has never generated a top line. The entire equity case rests on clinical candidates that are still in trials; the 10-K's own forward-looking language frames the risks plainly: 'our ability to develop and ultimately commercialize our current product candidates,' 'the success of nonclinical and clinical studies,' 'the need and ability to obtain regulatory approval,' and 'potential side effects of our product candidates that could delay or prevent commercialization.' Management even flags 'any potential strategic transaction involving us' and states outright that 'an investment in us [is] speculative and risky.' That is a binary, event-driven security — trial readouts and FDA decisions, not fundamentals, will move it — and the provided data gives no visibility into the pipeline's odds. That unknowable risk alone caps this at avoid for a self-directed retail investor.

The numbers reinforce the picture rather than soften it. Losses are widening sharply: net income fell to -$52.6M in FY2025 (YoY -198.8%) and operating income to -$56.4M (YoY -189.2%), driven by R&D that surged 157.1% to $32.7M as the company pushed candidates forward. Operating cash flow was -$35.8M. Against $97.6M of cash, that implies only roughly two to three years of runway before another raise is required — and the funding cost is already visible: shares outstanding ballooned 333.1% YoY to 17.2M, so existing holders have been massively diluted, and the $367M accumulated deficit shows how much capital has already been consumed with nothing to show on the revenue line. ROE is -54.2%.